Get notified when PASG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Company now discloses substantial doubt about ability to continue as a going concern due to recurring losses and cash usage.
Passage BIO flags going concern, launches strategic review as cash falls to $33M
Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read
Key Changes
-
high
Company disclosed substantial doubt about ability to continue as a going concern, citing recurring losses and negative cash flow. Cash position declined from $63.4M to $33.3M year-over-year.
Risk Factors: Going Concern verify on EDGAR → -
high
Board initiated strategic alternatives review on April 20, 2026, exploring merger, acquisition, reverse merger, asset sale, or partnerships. No assurance process will result in transaction.
Risk Factors: Strategic Review verify on EDGAR → -
high
Company removed prior cash runway estimate (previously projected into Q1 2027) despite $30M cash decline, suggesting heightened uncertainty about funding timeline.
Risk Factors: Cash Runway verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade PASG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify